RT Journal Article
SR Electronic
T1 Association study of <em>DNAJC13, UCHL1, HTRA2, GIGYF2</em> and <em>EIF4G1</em> with Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.26.20141176
DO 10.1101/2020.06.26.20141176
A1 Prabhjyot Saini
A1 Uladzislau Rudakou
A1 Eric Yu
A1 Jennifer A. Ruskey
A1 Farnaz Asayesh
A1 Sandra B. Laurent
A1 Dan Spiegelman
A1 Stanley Fahn
A1 Cheryl Waters
A1 Oury Monchi
A1 Yves Dauvilliers
A1 Nicolas Dupré
A1 Lior Greenbaum
A1 Sharon Hassin-Baer
A1 Alberto J. Espay
A1 Guy A. Rouleau
A1 Roy N. Alcalay
A1 Edward A. Fon
A1 Ronald B. Postuma
A1 Ziv Gan-Or
YR 2020
UL http://medrxiv.org/content/early/2020/06/28/2020.06.26.20141176.abstract
AB Rare mutations in genes originally discovered in multi-generational families have been associated with increased risk of Parkinson’s Disease (PD). The involvement of rare variants in DNAJC13, UCHL1, HTRA2, GIGYF2 and EIF4G1 loci have been poorly studied or produced conflicting results across cohorts. However, they are still being often referred to as “PD-genes” and used in different models. To further elucidate the role of these five genes in PD, we fully sequenced them using molecular inversion probes in 2,408 PD patients and 3,444 controls from 3 different cohorts. A total of 788 rare variants were identified across the five genes and three cohorts. Burden analyses and optimized sequence Kernel association tests revealed no significant association between any of the genes and PD after correction for multiple comparisons. Our results do not support an association of the five tested genes with PD. Combined with previous studies, it is unlikely that any of these genes plays an important role in PD. Their designation as “PARK” genes should be reconsidered.Competing Interest StatementSF received consulting fees/honoraria for board membership (unrelated to the current study) from Retrophin Inc., Sun Pharma Advanced Research Co., LTD and Kashiv Pharma. CW received consulting fees/honoraria (unrelated to the current study) from US World Meds, Acadia, Lundbeck, Cynapsus, Acorda. ND received consultancy fees (unrelated to the current work) from Actelion Pharmaceuticals. SHB received consulting fees from Actelion Pharmaceuticals Ltd., Abbvie Israel, Robotico Ltd., Medtronic Israel, Medison Pharma Israel (unrelated to the current study). AJE received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, InTrance, Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams &amp; Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Acadia, and Sunovion. RNA received consultation fees (unrelated to the current study) from Biogen, Denali, Genzyme/Sanofi and Roche. EAF Received consulting fees (unrelated to the current study) from Inception Sciences. ZGO received consulting fees (unrelated to the current study) from Denali, Inception Sciences (now Ventus), Idorsia, Lysosomal Therapeutics Inc., Prevail Therapeutics, Deerfield, Neuron23 and Handl Therapeutics. All other authors report no conflict of interest.Funding StatementThis work was financially supported by the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program and Parkinson Canada. The Columbia University cohort is supported by the Parkinson's Foundation, the National Institutes of Health [K02NS080915, and UL1 TR000040] and the Brookdale Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients and controls signed informed consent at enrollment and the study protocols were approved by the institutional review board of McGill University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data is available upon request by any qualified investigator.